This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 May;17(5):545-7.

doi: 10.1038/nm0511-545.

Window of opportunity for daclizumab

Kimberly S Schluns

PMID: 21546970
DOI: 10.1038/nm0511-545

Comment

Window of opportunity for daclizumab

Kimberly S Schluns. Nat Med. 2011 May.

. 2011 May;17(5):545-7.

doi: 10.1038/nm0511-545.

Author

Kimberly S Schluns

PMID: 21546970
DOI: 10.1038/nm0511-545

No abstract available

PubMed Disclaimer

Comment on

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B. Wuest SC, et al. Nat Med. 2011 May;17(5):604-9. doi: 10.1038/nm.2365. Epub 2011 May 1. Nat Med. 2011. PMID: 21532597 Free PMC article.

Similar articles

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B. Wuest SC, et al. Nat Med. 2011 May;17(5):604-9. doi: 10.1038/nm.2365. Epub 2011 May 1. Nat Med. 2011. PMID: 21532597 Free PMC article.
Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
Martin R. Martin R. Neurodegener Dis. 2008;5(1):23-6. doi: 10.1159/000109934. Neurodegener Dis. 2008. PMID: 18075271 Review.
IL-15R alpha-chain expression during anti-CD25 treatment of cardiac allograft recipients.
Baan CC, Balk AH, van der Plas AJ, van Gelder T, Vantrimpont PJ, Maat LP, Weimar W. Baan CC, et al. Transplant Proc. 2002 Dec;34(8):3243-5. doi: 10.1016/s0041-1345(02)03591-1. Transplant Proc. 2002. PMID: 12493434 No abstract available.
Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.
Tkaczuk J, Milford E, Yu C, Baksh S, Carpenter C, Burakoff S, McKay D. Tkaczuk J, et al. Transplant Proc. 2001 Feb-Mar;33(1-2):212-3. doi: 10.1016/s0041-1345(00)01978-3. Transplant Proc. 2001. PMID: 11266783 No abstract available.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA. Waldmann TA. J Clin Immunol. 2007 Jan;27(1):1-18. doi: 10.1007/s10875-006-9060-0. Epub 2007 Jan 11. J Clin Immunol. 2007. PMID: 17216565 Review.

See all similar articles

Cited by

Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster.
Kim M, Kim TJ, Kim HM, Doh J, Lee KM. Kim M, et al. Sci Rep. 2017 Jan 11;7:40623. doi: 10.1038/srep40623. Sci Rep. 2017. PMID: 28074895 Free PMC article.
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH. Rech AJ, et al. Sci Transl Med. 2012 May 16;4(134):134ra62. doi: 10.1126/scitranslmed.3003330. Sci Transl Med. 2012. PMID: 22593175 Free PMC article. Clinical Trial.
Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE, Rose JW. Baldassari LE, et al. Neurotherapeutics. 2017 Oct;14(4):842-858. doi: 10.1007/s13311-017-0553-8. Neurotherapeutics. 2017. PMID: 28707278 Free PMC article. Review.
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Wiendl H, Gross CC. Wiendl H, et al. Nat Rev Neurol. 2013 Jul;9(7):394-404. doi: 10.1038/nrneurol.2013.95. Epub 2013 Jun 4. Nat Rev Neurol. 2013. PMID: 23732529 Review.
Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.
Ramirez GA, Maugeri N, Sabbadini MG, Rovere-Querini P, Manfredi AA. Ramirez GA, et al. Clin Exp Immunol. 2014 Feb;175(2):150-66. doi: 10.1111/cei.12223. Clin Exp Immunol. 2014. PMID: 24128276 Free PMC article. Review.

See all "Cited by" articles

References

1. Immunity. 2002 Nov;17(5):537-47 - PubMed
1. J Immunol. 2010 Jul 15;185(2):1311-20 - PubMed
1. Nat Immunol. 2001 Sep;2(9):882-8 - PubMed
1. J Exp Med. 1987 Oct 1;166(4):1055-69 - PubMed
1. Mol Immunol. 2007 Mar;44(7):1544-50 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group